Nimodipine Tablets

Nimodipine is a Ca channel blocker. Under normal circumstances, the contraction of smooth muscle depends on the entry of Ca into the cell, which leads to the depolarization of transmembrane current. Nimodipine achieves the purpose of relieving vasospasm by effectively preventing Ca from entering the cell and inhibiting the contraction of smooth muscle. Animal experiments have shown that the effect of nimodipine on cerebral arteries is much stronger than that on arteries in other parts of the body, and because it has a high lipophilic characteristic, it is easy to pass through the blood-brain barrier. When used for the treatment of subarachnoid hemorrhage, the concentration in cerebrospinal fluid can reach 12.5ng/ml. It can be inferred that it can be used clinically to prevent vasospasm after subarachnoid hemorrhage, but the mechanism of action of this drug in human application is still unclear. In addition, it also has the effect of protecting and promoting memory and promoting intellectual recovery. Therefore, it can selectively act on cerebral vascular smooth muscle, dilate cerebral blood vessels, increase cerebral blood flow, and significantly reduce ischemic brain damage caused by vasospasm.

The main ingredient of this product is nimodipine.

This product is a light yellow tablet, odorless and tasteless. It is not stable to light, but relatively stable to moisture and heat.

It is suitable for improving blood circulation in the recovery period of acute cerebrovascular disease and cerebral vasospasm after subarachnoid hemorrhage due to various reasons.

1. Ischemic cerebrovascular disease: Oral, 30-120 mg (1.5-6 tablets) per day, divided into 3 times, for one month. 2. Migraine: Oral, 40 mg (2 tablets) per time, 3 times a day, 12 weeks as a course of treatment. The effective rate is 88%, about half of the cases can be basically cured or significantly effective, and it can reduce the pain degree, frequency and duration of attacks, and prevent the appearance of premonitory symptoms for vascular, tension, cluster and mixed headaches. 3. Cerebral vasospasm caused by subarachnoid hemorrhage: Oral, 40-60 mg (2-3 tablets) per time, 3-4 times a day, 3-4 weeks as a course of treatment. For patients who need surgery, stop taking the medicine on the day of surgery and continue taking it later. 4. Sudden deafness: 40-60 mg (2-3 tablets) per day, divided into 3 times, 5 days as a course of treatment, generally 3-4 courses of treatment. 5 Mild and moderate hypertension: Patients with hypertension and the above-mentioned cerebrovascular diseases can be given priority. Oral administration, 40 mg (2 tablets) at a time, 3 times a day, the maximum daily dose is 240 mg (12 tablets).

A large number of clinical practices have shown that when patients with subarachnoid hemorrhage are treated with nimodipine, about 11.2% of patients experience adverse reactions. The most common adverse reactions are: (1) Decreased blood pressure, the degree of which is related to the drug dose. (2) Hepatitis. (3) Skin irritation. (4) Gastrointestinal bleeding. (5) Thrombocytopenia. (6) Occasionally, transient dizziness, headache, facial flushing, vomiting, gastrointestinal discomfort, etc. In addition, after oral administration of nimodipine, some patients may experience an increase in alkaline phosphatase (ALP), lactate dehydrogenase (LDH), AKP, an increase in blood sugar, and an increase in platelet count in some individuals.

Not yet clear.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: 1. The drug can be secreted by breast milk, so it is not suitable for lactating women. 2. Animal experiments indicate that this product is teratogenic. Precautions for the elderly: Not yet clear.

(1) When used in combination with other calcium ion antagonists that act on the cardiovascular system, it can increase the efficacy of other calcium ion antagonists. (2) When nimodipine 90 mg/day is used in combination with cimetidine 1000 mg/day for more than one week, the blood concentration of nimodipine can increase by 50%, which may be related to the inhibition of nimodipine metabolism by cimetidine in the liver cytochrome P450

Keep away from light, tightly closed and in a dry place.

20mg per tablet

36 months.

Chiatai Qingchunbao Pharmaceutical Co., Ltd.

• Founded in:

  1992-11-06

• Address:

  No. 88, Qingchun Road, Moganshan National High-tech Zone, Deqing, Huzhou City, Zhejiang Province (Fuxi)

• Tax NO.:

  91330100609120766P

• Registered Funds:

  128.5 million yuan

• Website:

  Log in to view

• Email:

  Log in to view